Trimegestone + 17b Estradiol
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
84
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Postmenopause
Conditions
Postmenopause
Trial Timeline
Feb 1, 2005 โ Mar 1, 2007
NCT ID
NCT00195455About Trimegestone + 17b Estradiol
Trimegestone + 17b Estradiol is a approved stage product being developed by Pfizer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00195455. Target conditions include Postmenopause.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00195455 | Approved | Completed |
Competing Products
16 competing products in Postmenopause